Overview

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

Status:
Completed
Trial end date:
2021-01-08
Target enrollment:
Participant gender:
Summary
To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.
Phase:
Early Phase 1
Details
Lead Sponsor:
Taro Pharmaceuticals USA
Treatments:
Adapalene